liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Clinical trial: colectomy after rescue therapy in ulcerative colitis-3-year follow-up of the Swedish-Danish controlled infliximab study
Örebro University Hospital, Sweden.
Örebro University Hospital, Sweden.
Lund University Hospital, Sweden.
Sahlgrenska University Hospital, Göteborg, Sweden.
Vise andre og tillknytning
2010 (engelsk)Inngår i: Alimentary Pharmacology and Therapeutics, ISSN 0269-2813, E-ISSN 1365-2036, Vol. 32, nr 8, s. 984-989Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background The long-term efficacy of infliximab as rescue therapy in steroid-refractory ulcerative colitis is not well described.

Aim To examine the long-term efficacy of infliximab as a rescue therapy through a 3-year follow-up of a previous placebo-controlled trial of infliximab in acute steroid-refractory ulcerative colitis.

Method In the original study, 45 patients were randomized to a single infusion of infliximab 5 mg/kg or placebo, and at 3 months, 7/24 patients given infliximab were operated vs. 14/21 patients given placebo. Three years or later, patients were asked to participate in a clinical follow-up.

Results Another seven patients underwent colectomy during follow-up: five in the infliximab group and two in the placebo group. After 3 years, a total of 12/24 (50%) patients given infliximab and 16/21 (76%) given placebo (P = 0.012) had a colectomy. None of eight patients in endoscopic remission at 3 months later had a colectomy compared with 7/14 (50%) patients who were not in remission (P = 0.02). There was no mortality.

Conclusion The benefit of rescue therapy with infliximab in steroid-refractory acute ulcerative colitis remained after 3 years. The main advantage of infliximab treatment occurred during the first 3 months, whereas subsequent colectomy rates were similar in the two groups. Mucosal healing at 3 months influenced later risk of colectomy.

sted, utgiver, år, opplag, sider
Blackwell Publishing Ltd , 2010. Vol. 32, nr 8, s. 984-989
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-60515DOI: 10.1111/j.1365-2036.2010.04435.xISI: 000282221200004OAI: oai:DiVA.org:liu-60515DiVA, id: diva2:357039
Tilgjengelig fra: 2010-10-15 Laget: 2010-10-15 Sist oppdatert: 2017-12-12

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekst

Personposter BETA

Ström, Magnus

Søk i DiVA

Av forfatter/redaktør
Ström, Magnus
Av organisasjonen
I samme tidsskrift
Alimentary Pharmacology and Therapeutics

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 165 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf